Trial of Lu-177 DOTATATE (Lutathera ®) in Unlicensed Indications

Conditions: Bronchial and Thymic Neuroendocrine Tumour; Paraganglioma/ Phaeochromocytoma; Medullary Thyroid Carcinoma; Those Requiring Repeat Peptide Receptor Radionuclide Therapy Interventions: Drug: Lu-177 DOTATATE (Lutathera ®) Sponsors: University College, London Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials